Atorvastatin preconditioning improves the forward blood flow in the no-reflow rats

Fundamental and Clinical Pharmacology

Volumn 28, Issue 1, 2014, Pages 42-52

  Shao, Liang ^a,b   Zhang, Yong ^c   Ma, Aiqun ^b   Zhang, Ping ^a   Wu, Dayin ^a   Li, Wenzhu ^a   Wang, Jue ^d   Liu, Kun ^a   Wang, Zhaohui ^a  

^a UNION HOSPITAL   (China)

^b THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

^c XI'AN JIAOTONG UNIVERSITY   (China)

^d TONGJI HOSPITAL OF TONGJI MEDICAL COLLEGE OF HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Atorvastatin; Fibrinogen like protein 2; Myocardial ischemia reperfusion; No reflow; Tumor necrosis factor

Indexed keywords

ATORVASTATIN; FIBRINOGEN; FIBRINOGEN LIKE PROTEIN 2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD FLOW; CONTROLLED STUDY; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; INFLAMMATION; MALE; MICROCIRCULATION; MICROTHROMBUS; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; RAT;

ATORVASTATIN; FIBRINOGEN-LIKE PROTEIN 2; MYOCARDIAL ISCHEMIA/REPERFUSION; NO-REFLOW; TUMOR NECROSIS FACTOR-Α;

ANIMALS; ECHOCARDIOGRAPHY; FIBRINOGEN; FIBROSIS; HEMODYNAMICS; HEPTANOIC ACIDS; INFLAMMATION; MALE; MICROCIRCULATION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; MYOCYTES, CARDIAC; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; REGIONAL BLOOD FLOW; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84892555424     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2012.01074.x     Document Type: Article

References (37)

1. Eeckhout E., Kern M.J. The coronary no-reflow phenomenon: a review of mechanisms and therapies. Eur. Heart J. (2001) 22 729-739.
2. Rezkalla S.H., Kloner R.A. No-reflow phenomenon. Circulation (2002) 105 656-662.
3. Herrmann J. Peri-procedural myocardial injury: 2005 update. Eur. Heart J. (2005) 26 2493-2519.
4. Okamura A., Ito H., Iwakura K. et al. Detection of embolic particles with the Doppler guide wire during coronary intervention in patients with acute myocardial infarction: efficacy of distal protection device. J. Am. Coll. Cardiol. (2005) 45 212-215.
5. Verma S., Fedak P.W., Weisel R.D. et al. Fundamentals of reperfusion injury for the clinical cardiologist. Circulation (2002) 105 2332-2336.
6. Piana R.N., Paik G.Y., Moscucci M. et al. Incidence and treatment of 'no-reflow' after percutaneous coronary intervention. Circulation (1994) 89 2514-2518.
7. Diwan A., Dibbs Z., Nemoto S. et al. Targeted overexpression of noncleavable and secreted forms of tumor necrosis factor provokes disparate cardiac phenotypes. Circulation (2004) 109 262-268.
8. Kleinbongard P., Schulz R., Heusch G. TNF-a in myocardial ischemia/reperfusion, remodeling and heart failure. Heart Fail. Rev. (2011) 16 49-69.
9. Geng J., Zhao Z., Kang W.Q., Wang W., Zhang Y., Zhiming G.E. Atorvastatin reverses cardiac remodeling possibly through regulation of Protein Kinase D/Myocyte Enhancer Factor 2D activation in spontaneously hypertensive rats. Pharmacol. Res. (2010) 61 40-47.
10. Sun Y.M., Tian Y., Li Y. et al. Effect of atorvastatin on expression of IL-10 and TNF-alpha mRNA in myocardial ischemia-reperfusion injury in rats. Biochem. Biophys. Res. Commun. (2009) 382 336-340.
11. Shyu K.G., Chua S.K., Wang B.W., Kuan P. Mechanism of inhibitory effect of atorvastatin on resistin expression induced by tumor necrosis factor-α in macrophages. J. Biomed. Sci. (2009) 16 50.
12. Reffelmann T., Hale S.L., Li G., Kloner R.A. Relationship between no reflow and infarct size as influenced by the duration of ischemia and reperfusion. Am. J. Physiol Heart Circ. Physiol. (2002) 282 H766-H772.
13. Reffelmann T., Hale S.L., Dow J.S., Kloner R.A. No-reflow phenomenon persists long-term after ischemia/reperfusion in the rat and predicts infarct expansion. Circulation (2003) 108 2911-2917.
14. Kloner R.A., Ganote C.E., Jennings R.B. The 'no-reflow' phenomenon after temporary coronary occlusion in the dog. J. Clin. Invest. (1974) 54 1496-1508.
15. Ti Y., Xie G.L., Wang Z.H. et al. TRB3 gene silencing alleviates diabetic cardiomyopathy in a type 2 diabetic rat model. Diabetes (2011) 60 2963-2974.
16. Sun M., Dawood F., Wen W.H. et al. Excessive tumor necrosis factor activation after infarction contributes to susceptibility of myocardial rupture and left ventricular dysfunction. Circulation (2004) 110 3221-3228.
17. Kerckhoven R., Kalkman E.A., Saxena P.R., Schoemaker R.G. Altered cardiac collagen and associated changes in diastolic function of infarcted rat hearts. Cardiovasc. Res. (2000) 46 316-323.
18. Sun M., Chen M., Dawood F. et al. Tumor necrosis factor-alpha mediates cardiac remodeling and ventricular dysfunction after pressure overload state. Circulation (2007) 115 1398-1407.
19. Shao L., Wu D., Zhang P. et al. The significance of microthrombosis and fgl2 in no-reflow phenomenon of rats with acute myocardial ischemia/reperfusion. Clin. Appl. Thromb. Hemost. (2012) Mar 5. [Epub ahead of print].
20. Arras M., Höche A., Bohle R., Eckert P., Riedel W., Schaper J. Tumor necrosis factor- a in macrophages of heart, liver, kidney, and in the pituitary gland. Cell Tissue Res. (1996) 285 39-49.
21. Frangogiannis N.G., Lindsey M.L., Michael L.H. et al. Resident cardiac mast cells degranulate and release preformed TNF- a, initiating the cytokine cascade in experi-mental canine myocardial ischemia/reperfusion. Circulation (1998) 98 699-710.
22. Belosjorow S., Bolle I., Duschin A., Heusch G., Schulz R. TNF-α antibodies are as effective as ischemic preconditioning in reducing infarct size in rabbits. Am. J. Physiol. Heart Circ. Physiol. (2003) 284 H927-H930.
23. Gu Q., Yang X.P., Bonde P., DiPaula A., Fox-Talbot K., Becker L.C. Inhibition of TNF- a reduces myocardial injury and pro-inflammatory pathways following ischemia-reperfusion in the dog. J. Cardiovasc. Pharmacol. (2006) 48 320-328.
24. Whittaker P., Boughner D.R., Kloner R.A. Role of collagen in acute myocardial infarct expansion. Circulation (1991) 84 2123-2134.
25. Li Y.Y., Feng Q., Kadokami T. et al. Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor a can be modulated by anti-tumor necrosis factor a therapy. Proc. Natl Acad. Sci. U.S.A. (2000) 97 12746-12751.
26. Li Y.Y., Kadokami T., Wang P., McTiernan C.F., Feldman A.M. MMP inhibition modulates TNF- a transgenic mouse phenotype early in the development of heart failure. Am. J. Physiol Heart Circ. Physiol. (2002) 282 H983-H989.
27. Westermann D., Van Linthout S., Dhayat S. et al. Tumor necrosis factor-alpha antagonism protects from myocardial inflammation and fibrosis in experi-mental diabetic cardiomyopathy. Basic Res. Cardiol. (2007) 102 500-507.
28. Reffelmann T., Kloner R.A. The 'no-reflow' phenomenon: basic science and clinical correlates. Heart (2002) 87 162-168.
29. Hamm C.W., Bassand J.P., Agewall S. et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur. Heart J. (2011) 32 2999-3054.
30. Patti G., Pasceri V., Colonna G. et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J. Am. Coll. Cardiol. (2007) 49 1272-1278.
31. Reagan-Shaw S., Nihal M., Ahmad N. Dose translation from animal to human studies revisited. FASEB J. (2008) 22 659-661. Epub 2007 Oct 17.
32. Zhu C.L., Yan W.M., Zhu F. et al. Fibrinogen-like protein 2 fibroleukin expression and its correlation with disease progression in murine hepatitis virus type 3-induced fulminant hepatitis and in patients with severe viral hepatitis B. World J. Gastroenterol. (2005) 11 6936-6940.
33. Han M., Yan W., Huang Y. et al. The Nucleocapsid protein of SARS-CoV induces transcription of hfgl2 prothrombinase gene dependent on C/EBP alpha. J. Biochem. (2008) 144 51-62.
34. Shalev I., Liu H., Koscik C. et al. Targeted deletion of fgl2 leads to impaired regulatory T cell activity and development of autoimmune glomerulonephritis. J. Immunol. (2015) 180 249-260.
35. Ghanekar A., Mendicino M., Liu H. et al. Endothelial induction of fgl2 contributes to thrombosis during acute vascular xenograft rejection. J. Immunol. (2004) 172 5693-5701.
36. Marazzi S., Blum S., Hartmann R. et al. Characterization of human fibroleukin, a fibrinogen-like protein secreted by T lymphocytes. J. Immunol. (1998) 161 138-147.
37. Su K., Chen F., Yan W.M. et al. Fibrinogen-like protein 2/fibroleukin prothrombinase contributes to tumor hypercoagulability via IL-2 and IFN-γ. World J. Gastroenterol. (2008) 14 5980-5989.